K. Barrett

发表

Inhibition of the kinase ITK in a mouse model of asthma reduces cell death and fails to inhibit the inflammatory response

J. DeVoss, A. Zarrin, Lawren C. Wu, 2015, Science Signaling.

Lung-restricted inhibition of Janus kinase 1 is effective in rodent models of asthma

Adam R. Johnson, N. C. Ray, G. Cain, 2018, Science Translational Medicine.

NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus

Adam R. Johnson, Z. Modrušan, J. DeVoss, 2018, Nature Communications.

NF-κB inducing kinase is a therapeutic target for systemic lupus erythematosus

Adam R. Johnson, Z. Modrušan, J. DeVoss, 2018, Nature Communications.

A Restricted Role for TYK2 Catalytic Activity in Human Cytokine Responses Revealed by Novel TYK2-Selective Inhibitors

Adam R. Johnson, Jun Liang, N. Lewin-Koh, 2013, The Journal of Immunology.

Revealed by Novel TYK2-Selective Inhibitors Activity in Human Cytokine Responses A Restricted Role for TYK2 Catalytic

Adam R. Johnson, N. Lewin-Koh, Lawren C. Wu, 2013 .

In Vitro and In Vivo Inhibition of the T315I Mutant BCR/ABL Kinase.

A. McPherson, G. Noronha, J. Hood, 2006 .

Lead optimization of a 4-aminopyridine benzamide scaffold to identify potent, selective, and orally bioavailable TYK2 inhibitors.

Adam R. Johnson, Jun Liang, J. DeVoss, 2013, Journal of medicinal chemistry.

Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Ignacio Aliagas, 2013, Journal of medicinal chemistry.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Tian Jin, 2012, Journal of medicinal chemistry.

Discovery of [7-(2,6-dichlorophenyl)-5-methylbenzo [1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]amine--a potent, orally active Src kinase inhibitor with anti-tumor activity in preclinical assays.

Hong Zhu, Feng Shi, Steven Hu, 2007, Bioorganic & medicinal chemistry letters.

Discovery and preliminary structure-activity relationship studies of novel benzotriazine based compounds as Src inhibitors.

Joel Renick, Kathy Barrett, Richard Soll, 2006, Bioorganic & medicinal chemistry letters.

Lead identification of novel and selective TYK2 inhibitors.

Adam R. Johnson, Jun Liang, M. Ultsch, 2013, European journal of medicinal chemistry.

Targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study

Dhara N. Amin, N. Johnson, M. Krem, 2023, American journal of hematology.

Direct Tie2 Agonists Stabilize Vasculature for the Treatment of Diabetic Macular Edema

R. Rowntree, Vahan B. Indjeian, Minhong Yan, 2022, Translational vision science & technology.

Tetrahydroindazoles as Interleukin-2 Inducible T-Cell Kinase Inhibitors. Part II. Second-Generation Analogues with Enhanced Potency, Selectivity, and Pharmacodynamic Modulation in Vivo.

P. McEwan, J. DeVoss, A. Zarrin, 2015, Journal of medicinal chemistry.

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.

Adam R. Johnson, Jun Liang, J. DeVoss, 2017, Bioorganic & medicinal chemistry letters.

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Charles Eigenbrot, 2012, Bioorganic & medicinal chemistry letters.

Discovery of potent and selective pyrazolopyrimidine janus kinase 2 inhibitors.

Jane R Kenny, Michael Siu, Deepak Sampath, 2012, Journal of medicinal chemistry.

Design and evaluation of novel 8-oxo-pyridopyrimidine Jak1/2 inhibitors.

Jane R Kenny, Charles Eigenbrot, Micah Steffek, 2013, Bioorganic & medicinal chemistry letters.

Nanolipoprotein particles (NLPs) as a delivery platform for Fab based therapeutics.

Y. Franke, Hong Li, Inna Zilberleyb, 2020, Bioconjugate chemistry.

Structure Based Design of Potent Selective Inhibitors of Protein Kinase D1 (PKD1).

Jianwen A. Feng, P. McEwan, R. Godemann, 2019, ACS medicinal chemistry letters.

2-Amino-[1,2,4]triazolo[1,5-a]pyridines as JAK2 inhibitors.

M. Ultsch, C. Eigenbrot, Leslie B. Lee, 2013, Bioorganic & medicinal chemistry letters.

Structure-based discovery of C-2 substituted imidazo-pyrrolopyridine JAK1 inhibitors with improved selectivity over JAK2.

Adam R. Johnson, Rohan V Mendonca, M. Ultsch, 2012, Bioorganic & medicinal chemistry letters.